A 32-year-old female is on long-term treatment for Rheumatoid ahritis. Fundus examination was done on follow up visit. What is the most probable drug responsible for this?
First, I need to recall the common drugs used for rheumatoid arthritis that have ophthalmological side effects. The main drugs for RA include methotrexate, biologics like TNF inhibitors, NSAIDs, and others. Methotrexate is a common DMARD and is known for various side effects, including liver toxicity and pulmonary issues. But does it affect the eyes?
Wait, I remember that hydroxychloroquine is an antimalarial drug used in RA and lupus. It's well-known for causing retinopathy, specifically chorioretinopathy. The fundus changes with hydroxychloroquine are typically a bull's-eye maculopathy. So if the patient is on hydroxychloroquine, a fundus exam would detect that.
Another possibility is chloroquine, but hydroxychloroquine is more commonly used now. Then there's methotrexate, but its ocular side effects are less common. Maybe the question is testing knowledge of antimalarials' retinal toxicity.
The options are missing, but the correct answer is likely hydroxychloroquine. The other options might include drugs like methotrexate, sulfasalazine, or biologics. The key point is the fundus exam indicating retinal changes, which are classic for hydroxychloroquine. So the explanation would focus on that.
**Core Concept**
This question tests knowledge of ophthalmologic adverse effects of long-term rheumatoid arthritis (RA) medications. Hydroxychloroquine, an antimalarial disease-modifying antirheumatic drug (DMARD), is notorious for causing **hydroxychloroquine retinopathy**, detectable via fundus examination as a bull’s-eye maculopathy.
**Why the Correct Answer is Right**
Hydroxychloroquine accumulates in the retinal pigment epithelium, causing progressive toxicity to the macula. The pathophysiology involves phospholipidosis and oxidative stress in retinal cells. Early detection via funduscopy or optical coherence tomography (OCT) is critical, as irreversible vision loss occurs after significant retinal damage. Annual ophthalmologic screening is mandatory for patients on long-term hydroxychloroquine therapy.
**Why Each Wrong Option is Incorrect**
**Option A:** Methotrexate is a folic acid antagonist used in RA, but its side effects include hepatotoxicity and pulmonary fibrosis—not retinopathy.
**Option B:** Sulfasalazine, a sulfapyridine-based DMARD, may cause allergic reactions or hepatotoxicity but lacks ophthalmologic toxicity.
**Option C:** TNF-α inhibitors (e.g., infliximab) are biologic DMARDs associated with opportunistic infections, not retinal lesions.
**Clinical Pearl / High-Yield Fact**
Never prescribe hydroxychloroquine without baseline and annual eye exams. The FDA mandates a cumulative dose threshold (5,220 g) before retinopathy risk becomes significant, but early screening is vital. Use the mnemonic **"Hy